Adenosine Receptors in Neurology and Psychiatry

Erscheinungsjahr 2014
ISBN: 978-0-12-801022-8
Verlag: William Andrew Publishing

Buch, Englisch, 524 Seiten, Format (B × H): 152 mm x 229 mm, Gewicht: 910 g

This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on adenosine receptor science, providing insights useful for actual drug discovery/development in neurology and psychiatry areas.

Zielgruppe

<p>People working for: basic neuroscience, purinergic science, neurology and psychiatry; investors and businesses in pharmaceutical R&D; medical doctors and care givers.</p>

Autoren/Hrsg.

Weitere Mitwirkende

Mori, Akihisa

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Psychiatrie, Sozialpsychiatrie, Suchttherapie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Neuropharmakologie, Psychopharmakologie

Inhaltsverzeichnis

- Adenosine Receptor Neurobiology: Overview

Jiang-Fan Chen, Chien-fei Lee and Yijuang Chern

- Adenosine Receptor PET Imaging in Human Brain

Masahiro Mishina and Kiich Ishiwata

- An Overview of Adenosine A2A Receptor Antagonists in Parkinson's Disease

Peter Jenner

- Mode of Action of Adenosine A2A Receptor Antagonists as Symptomatic Treatment for Parkinson's Disease

Akihisa Mori

- Adenosine Receptors and Dyskinesia in Pathophysiology

Masahiko Tomiyama

- Clinical/Pharmacological Aspect of Adenosine A2A Receptor Antagonist for Dyskinesia

Tomoyuki Kanda and Shin-ichi Uchida

- Interaction of Adenosine Receptors With Other Receptors from Therapeutic Perspective in Parkinson's Disease

Nicolas Morin and Thérèse Di Paolo

- Effects of the Adenosine A2A Receptor Antagonist on Cognitive Dysfunction in Parkinson's Disease

Shin-ichi Uchida, Takako Kadowaki-Horita and Tomoyuki Kanda

- Clinical Non-Motor Aspect of A2A Antagonist in PD Treatment

Masahiro Nomoto, Masahiro Nagai and Noriko Nishikawa

- Adenosine Receptors and Huntington's Disease

Chien-fei Lee and Yijuang Chern

- Adenosine Receptors and Epilepsy: Established Evidence and Perennial Potential

Susan A. Masino, Masahito Kawamura, Jr. and David N. Ruskin

- Adenosine Receptor Control of Cognition in Normal and Disease

Jiang-Fan Chen

- Adenosine Receptors in Cerebral Ischemia

Alessia Melani, Anna Maria Pugliese, and Felicita Pedata

- Roles of Adenosine and its Receptors in Sleep-Wake Regulation

Zhi-Li Huang, Ze Zheng and Wei-Min Qu

- Involvement of Adenosine A2A Receptors in Depression and Anxiety

Koji Yamada, Minoru Kobayashi and Tomoyuki Kanda

- The Adenosine Neuromodulation System in SchizophreniaDaniel Rial, Diogo R. Lara and Rodrigo A. Cunha

Über Autor(innen)

Mori, Akihisa
Akihisa Mori, PhD., Deputy Director, Strategic Product Portfolio Department, Kyowa Hakko Kirin Co., Ltd. Tokyo, Japan. He has been leading adenosine A2A receptor science, intensively and extensively researching and discovering physiological functions of adenosine A2A receptor for brain motor control, and through such a tremendous scientific work, has also been working for a first-in-class Adenosine A2A receptor antagonist as new medication for Parkinson's Disease, for more than 20 years, from its discovery stage to filing both US and Japan NDA, which has been launched in Japan (2013). He was graduated from Faculty of Pharmaceutical Sciences, Kyoto University in 1985, and obtained Ph.D. degree from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo in 1996. With number of publications in peer review journals in neuroscience field (e.g., J. Neuroscience, Neurology, J. Physiology, Annals of Neurology, British J Pharmacology etc.), he has given more than 20 lectures/podium talks for academia/universities and international conferences on various subjects (e.g., neurophysiology, adenosine receptor science, Parkinson's Disease, global drug development etc.) held not only in Japan but also in UK, Germany, Australia, Austria, and USA. In summary, he has greatly been contributing to translate from basic science of adenosine biology to practical drug development for adenosine receptor ligand in neurology area.